Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells
Sign Up to like & getrecommendations! Published in 2022 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfac271
Abstract: ABSTRACT Background Calciprotein particles (CPPs), colloidal mineral-protein nanoparticles, have emerged as potential mediators of phosphate toxicity in dialysis patients, with putative links to vascular calcification, endothelial dysfunction and inflammation. We hypothesized that phosphate binder therapy… read more here.
Keywords: dialysis patients; dialysis; phosphate binder; calciprotein particles ... See more keywords
Can Helicobacter pylori Colonization Affect the Phosphate Binder Pill Burden in Dialysis Patients?
Sign Up to like & getrecommendations! Published in 2019 at "Therapeutic Apheresis and Dialysis"
DOI: 10.1111/1744-9987.13443
Abstract: Phosphate binder pill (PBP) burden is a significant problem in dialysis patients. Phosphate absorption through the paracellular pathway increases in relatively acidic pH. In this study, we evaluated the effect of factors contributing to duodenal… read more here.
Keywords: binder pill; pbp burden; dialysis patients; phosphate binder ... See more keywords
Real-World Phosphate Binder Use Among Dialysis-Dependent Patients With CKD.
Sign Up to like & getrecommendations! Published in 2023 at "Nephron"
DOI: 10.1159/000530230
Abstract: INTRODUCTION For patients with chronic kidney disease (CKD), the need for phosphate binder (PB) treatment peaks at onset of dialysis. This real-world study assessed rates of PB utilization and switching in patients with dialysis-dependent CKD… read more here.
Keywords: dialysis dependent; ferric citrate; dialysis; phosphate binder ... See more keywords